Sept 26 (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
EMA said new data raise serious concerns about the safety of Oxbryta and added that the authorization, marketing and supply of the medicine be suspended until all the available data have been assessed in the ongoing review.
Late on Wednesday, Pfizer said it was withdrawing Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
((Christy.Santhosh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments